Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA:688806)
China · Delayed Price · Currency is CNY 30.67
+5.11 (19.99%)
Sep 30, 2026, 4:00 PM EDT
SHA:688806 Revenue
Zhuhai Trinomab Pharmaceutical had revenue of 51.31M CNY in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 116.93M. In the year 2025, Zhuhai Trinomab Pharmaceutical had annual revenue of 51.22M with 240.23% growth. That makes Zhuhai Trinomab Pharmaceutical the world's 34,560th largest company by revenue and 5,108th in China.
Revenue (ttm)
116.93M
Revenue Growth
+240.23%
P/S Ratio
120.80
Revenue / Employee
133.48K
Employees
876
Market Cap
14.12B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.22M | 36.17M | 240.23% |
| Dec 31, 2024 | 15.06M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 4.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.